DOI: https://doi.org/10.15587/2519-4798.2017.100177

Вплив гіполіпідемічних засобів на рівень модуляторів стеатогенезу та фіброгенезу у щурів з неалкогольною жировою хворобою печінки, асоційованою з гіпергомоцистеїнемією

Natalia Zaichko, Dar`ia Nekrut

Анотація


Досліджено вплив гіполіпідемічних засобів на рівень модуляторів стеатогенезу та фіброгенезу у щурів з неалкогольною жировою хворобою печінки, асоційованою з гіпергомоцистеїнемією. Показано, що препарат омега-3 поліненасичених жирних кислот ефективніше, порівняно з симвастатином, зменшує рівень профіброгенних медіаторів (гомоцистеїну, TNF-α), коригує дефіцит антифіброзних медіаторів (H2S, IGF-1), зменшує біохімічні ознаки стеатозу та фіброзу печінки

Ключові слова


гомоцистеїн; гідроген сульфід; інсуліноподібний фактор росту-1; стеатоз; фіброз; симвастатин; омега-3 поліненасичені жирні кислоти

Повний текст:

PDF

Посилання


Babak, O. J., Kolesnikova, E. V. (2012). Nealkogol'naja zhirovaja bolezn' pecheni i kardiovaskuljarnyj risk: sovremennyj vzgljad na problemu, optimizacija terapii [Non-alcoholic fatty liver disease and cardiovascular risk: a modern view of the problem, optimization of therapy]. Gastroenterology, 5, 68–70.

Adaptovana klinichna nastanova «Nealkoholna zhyrova khvoroba pechinky» [Adapted clinical guidelines "Nonalcoholic fatty liver disease"]. Ministry of Health of Ukraine, No. 826. Available at: http://mtd.dec.gov.ua/images/dodatki/2014_826Gepatyty/2014_826_AKN_ANGHP.pdf

Ahmed, M. (2015). Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology, 7 (11), 1450. doi: 10.4254/wjh.v7.i11.1450

Velychko, V. I., Kolotvina, L. I., Hur’iev, A. M., Klotvin, A. O. (2014). Ozhyrinnia i nealkoholna zhyrova khvoroba pechinky z pozytsii kardiovaskuliarnoho ryzyku v praktytsi simeinoho likaria [Obesity and nonalcoholic fatty liver disease with cardiovascular risk positions in the practice of family doctor]. Medicine of Ukrainian transport, 1, 79–82.

Pentiuk, N. O. (2011). Metabolichni predyktory fibrozu pechinky u khvorykh na khronichni hepatyty [Metabolic predictors of liver fibrosis in patients with chronic hepatitis]. Experimental and Clinical Medicine, 1 (50), 134–138.

Zvjaginceva, T. D., Glushhenko, S. V. (2014). Nealkogol'nyj steatogepatit i metody patogeneticheskoj korrekcii [Nonalcoholic steatohepatitis and methods of pathogenetic correction]. International Medical Journal, 20 (2 (78)), 29–32.

Pentiuk, N. O. (2009). Vplyv hiperhomotsysteinemii na formuvannia CCl4-indukovanoho fibrozu pechinky u shchuriv [The influence of hyperhomocysteinemia on formation CCl4-induced liver fibrosis in rats]. Modern gastroenterology, 5 (49), 33–37.

Tan, G., Pan, S., Li, J., Dong, X., Kang, K., Zhao, M. et. al. (2011). Hydrogen Sulfide Attenuates Carbon Tetrachloride-Induced Hepatotoxicity, Liver Cirrhosis and Portal Hypertension in Rats. PLoS ONE, 6 (10), e25943. doi: 10.1371/journal.pone.0025943

Zhang, Q., Zhang, Z. X., Fang, Q. et. al. (2012). Expression and significance of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in hepatocyte steatosis model. Zhonghua Gan Zang Bing Za Zhi, 20 (3), 196–200.

Zaichko, N. V. (2014). Hydrogen sulfide: metabolism, biological and medical role. The Ukrainian Biochemical Journal, 86 (5), 5–25. doi: 10.15407/ubj86.05.005

Sun, L., Zhang, S., Yu, C., Pan, Z., Liu, Y., Zhao, J. et. al. (2015). Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. American Journal of Physiology – Endocrinology and Metabolism, 309 (11), E925–E935. doi: 10.1152/ajpendo.00294.2015

Inzaghi, E., Cianfarani, S., Nobili, V. (2014). Insulin-like growth factors (IGF-I and -II): new actors in the development of non-alcoholic fatty liver disease. Expert Review of Endocrinology & Metabolism, 9 (3), 193–195. doi: 10.1586/17446651.2014.900438

Aguirre, G. A., De Ita, J. R., de la Garza, R. G., Castilla-Cortazar, I. (2016). Insulin-like growth factor-1 deficiency and metabolic syndrome. Journal of Translational Medicine, 14 (1). doi: 10.1186/s12967-015-0762-z

Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. et. al. (2012). The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. The American Journal of Gastroenterology, 107 (6), 811–826. doi: 10.1038/ajg.2012.128

Unifikovanyj klinichnyj protokol pervynnoi', vtorynnoi' (specializovanoi') medychnoi' dopomogy. Nealkogol'nyj steatogepatyt (2014). Order of the Ministry of Health of Ukraine, No. 826. Available at: http://mtd.dec.gov.ua/images/dodatki/2014_826Gepatyty/2014_826_YKPMD_NSTPT.pdf

Pooya, S., Jalali, M. D., Jazayery, A. D., Saedisomeolia, A., Eshraghian, M. R., Toorang, F. (2010). The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases, 20 (5), 326–331. doi: 10.1016/j.numecd.2009.04.002

Soboleva, E. V. (2007). Gomocisteinemija kak mishen' terapevticheskogo vozdejstvija u bol'nyh ishemicheskoj bolezn'ju serdca. Jeffekty simvastatina [Homocysteinemia as a target of therapeutic effect in patients with coronary heart disease. Effects of simvastatin]. RMJ, 5, 340.

Vladimirova-Kitova, L. G., Deneva, T. I., Marinov, B. (2010). Effect of Moderate and High-Dose Simvastatin on Asymmetric Dimethylarginine-Homocysteine Metabolic Pathways in Patients with Newly Detected Severe Hypercholesterolemia. Cardiovascular Therapeutics, 29 (5), 340–348. doi: 10.1111/j.1755-5922.2010.00149.x

Jiang, S., Chen, Q., Venners, S. A., Zhong, G., Hsu, Y.-H., Xing, H. et. al. (2013). Effect of Simvastatin on Plasma Homocysteine Levels and Its Modification by MTHFR C677T Polymorphism in Chinese Patients with Primary Hyperlipidemia. Cardiovascular Therapeutics, 31 (4), e27–e33. doi: 10.1111/1755-5922.12002

Nekrut, D. O. (2016). Vplyv hiperhomotsysteinemii na formuvannia nealkoholnoi zhyrovoi khvoroby pechinky u shchuriv [Influence of hyperhomocysteinemia on nonalcoholic fatty liver disease formation in rats]. Visnyk morfolohii, 22 (1), 40–45.

Wilinski, B., Wilinski, J., Somogyi, E., Piotrowska, J., Goralska, M., Macura, B. (2011). Carvedilol Induces Endogenous Hydrogen Sulfide Tissue Concentration Changes in Various Mouse Organs. Folia Biologica, 59 (3), 151–155. doi: 10.3409/fb59_3-4.151-155

Pentiuk, А. А., Gutcol, V. I., Iakovleva, O. A. (1987). Opredelenie fosfolipidov po obrazovaniiu gidrofobnogo kompleksa s ferotiotcianatom ammoniia [Determination of phospholipids by the formation of a hydrophobic complex with ammonium ferrotiocyanate]. Lab. delo, 6, 457–459.

Siddiqi, N. J., Alhomida, A. S. (2003). Investigation into the Distribution of Total, Free, Peptide-bound, Protein-bound, Soluble-and Insoluble-Collagen Hydroxyproline in Various Bovine Tissues. BMB Reports, 36 (2), 154–158. doi: 10.5483/bmbrep.2003.36.2.154

Martinez-Vega, R., Partearroyo, T., Vallecillo, N., Varela-Moreiras, G., Pajares, M. A., Varela-Nieto, I. (2015). Long-term omega-3 fatty acid supplementation prevents expression changes in cochlear homocysteine metabolism and ameliorates progressive hearing loss in C57BL/6J mice. The Journal of Nutritional Biochemistry, 26 (12), 1424–1433. doi: 10.1016/j.jnutbio.2015.07.011

Huang, T., Wahlqvist, M. L., Li, D. (2010). Docosahexaenoic acid decreases plasma homocysteine via regulating enzyme activity and mRNA expression involved in methionine metabolism. Nutrition, 26 (1), 112–119. doi: 10.1016/j.nut.2009.05.015

Huang, T., Wahlqvist, M. L., Li, D. (2012). Effect of n-3 polyunsaturated fatty acid on gene expression of the critical enzymes involved in homocysteine metabolism. Nutrition Journal, 11 (1). doi: 10.1186/1475-2891-11-6

Mikael, L. G., Rozen, R. (2008). Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF- B/iNOS. Cardiovascular Research, 80 (1), 151–158. doi: 10.1093/cvr/cvn157

Sekine, Y., Furuya, Y., Nishii, M., Koike, H., Matsui, H., Suzuki, K. (2008). Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochemical and Biophysical Research Communications, 372 (2), 356–361. doi: 10.1016/j.bbrc.2008.05.043

Shibata, T., Tamura, M., Kabashima, N., Serino, R., Tokunaga, M., Matsumoto, M. et. al. (2009). Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. Life Sciences, 84 (21-22), 725–731. doi: 10.1016/j.lfs.2009.02.022

Forbes, K., Shah, V. K., Siddals, K., Gibson, J. M., Aplin, J. D., Westwood, M. (2014). Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation. MHR: Basic Science of Reproductive Medicine, 21 (1), 105–114. doi: 10.1093/molehr/gau093

Jang, H., Hong, E., Park, S., Byun, H., Koh, D., Choi, M. et. al. (2016). Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation. Oncology Letters, 12 (1), 250–256. doi: 10.3892/ol.2016.4569

Tran, L. V., Malla, B. A., Sharma, A. N., Kumar, S., Tyagi, N., Tyagi, A. K. (2016). Effect of omega-3 and omega-6 polyunsaturated fatty acid enriched diet on plasma IGF-1 and testosterone concentration, puberty and semen quality in male buffalo. Animal Reproduction Science, 173, 63–72. doi: 10.1016/j.anireprosci.2016.08.012

Gholamhosseini, S., Nematipour, E., Djazayery, A., Javanbakht, M. H., Koohdani, F., Zareei, M., Djalali, M. (2015). ω-3 fatty acid differentially modulated serum levels of IGF1 and IGFBP3 in men with CVD: A randomized, double-blind placebo-controlled study. Nutrition, 31 (3), 480–484. doi: 10.1016/j.nut.2014.09.010


Пристатейна бібліографія ГОСТ


Бабак, О. Я. Неалкогольная жировая болезнь печени и кардиоваскулярный риск: современный взгляд на проблему, оптимизация терапии [Текст] / О. Я. Бабак, Е. В. Колесникова // Гастроентерологія. – 2012. – № 5. – С. 68–70.

Неалкогольна жирова хвороба печінки [Текст]. – Наказ МОЗ України, 2014. – № 826 – Режим доступу: http://mtd.dec.gov.ua/images/dodatki/2014_826Gepatyty/2014_826_AKN_ANGHP.pdf

Ahmed, M. Non-alcoholic fatty liver disease in 2015 [Text] / M. Ahmed // World Journal of Hepatology. – 2015. – Vol. 7, Issue 11. – P. 1450. doi: 10.4254/wjh.v7.i11.1450 

Величко, В. І. Ожиріння й неалкогольна жирова хвороба печінки з позиції кардіоваскулярного ризику в практиці сімейного лікаря [Текст] / В. І. Величко, Л. І. Колотвіна, А. М. Гур’єв, А. О. Клотвін // Медицина транспорту України. – 2014. – № 1. – С. 79–82.

Пентюк, Н. О. Метаболічні предиктори фіброзу печінки у хворих на хронічні гепатити [Текст] / Н. О. Пентюк // Експериментальна та клінічна медицина. – 2011. – № 1 (50). – С. 134–138.

Звягинцева, Т. Д. Неалкогольный стеатогепатит и методы патогенетической коррекции [Текст] / Т. Д. Звягинцева, С. В. Глущенко // Міжнародний медичний журнал. – 2014. – Т. 20, № 2 (78). – С. 29–32.

Пентюк, Н. О. Вплив гіпергомоцистеїнемії на формування CCl4-індукованого фіброзу печінки у щурів [Текст] / Н. О. Пентюк // Сучасна гастроентерологія. – 2009. – № 5 (49). – С. 33–37.

Tan, G. Hydrogen Sulfide Attenuates Carbon Tetrachloride-Induced Hepatotoxicity, Liver Cirrhosis and Portal Hypertension in Rats [Text] / G. Tan, S. Pan, J. Li, X. Dong, K. Kang, M. Zhao et. al. // PLoS ONE. – 2011. – Vol. 6, Issue 10. – P. e25943. doi: 10.1371/journal.pone.0025943 

Zhang, Q. Expression and significance of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in hepatocyte steatosis model [Text] / Q. Zhang, Z. X. Zhang, Q. Fang et. al. // Zhonghua Gan Zang Bing Za Zhi. – 2012. – Vol. 20, Issue 3. – P. 196–200.

Zaichko, N. V. Hydrogen sulfide: metabolism, biological and medical role [Text] / N. V. Zaichko // The Ukrainian Biochemical Journal. – 2014. – Vol. 86, Issue 5. – P. 5–25. doi: 10.15407/ubj86.05.005 

Sun, L. Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway [Text] / L. Sun, S. Zhang, C. Yu, Z. Pan, Y. Liu, J. Zhao et. al. // American Journal of Physiology – Endocrinology and Metabolism. – 2015. – Vol. 309, Issue 11. – P. E925–E935. doi: 10.1152/ajpendo.00294.2015 

Inzaghi, E. Insulin-like growth factors (IGF-I and -II): new actors in the development of non-alcoholic fatty liver disease [Text] / E. Inzaghi, S. Cianfarani, V. Nobili // Expert Review of Endocrinology & Metabolism. – 2014. – Vol. 9, Issue 3. – P. 193–195. doi: 10.1586/17446651.2014.900438 

Aguirre, G. A. Insulin-like growth factor-1 deficiency and metabolic syndrome [Text] / G. A. Aguirre, J. Rodriguez De Ita, R. G. de la Garza, I. Castilla-Cortazar // Journal of Translational Medicine. – 2016. – Vol. 14, Issue 1. doi: 10.1186/s12967-015-0762-z 

Chalasani, N. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [Text] / N. Chalasani, Z. Younossi, J. E. Lavine, A. M. Diehl, E. M. Brunt, K. Cusi et. al. // The American Journal of Gastroenterology. – 2012. – Vol. 107, Issue 6. – P. 811–826. doi: 10.1038/ajg.2012.128 

Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) медичної допомоги. Неалкогольний стеатогепатит [Текст]. – Наказ МОЗ України, 2014. – № 826 – Режим доступу: http://mtd.dec.gov.ua/images/dodatki/2014_826Gepatyty/2014_826_YKPMD_NSTPT.pdf

Pooya, S. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients [Text] / S. Pooya, M. D. Jalali, A. D. Jazayery, A. Saedisomeolia, M. R. Eshraghian, F. Toorang // Nutrition, Metabolism and Cardiovascular Diseases. – 2010. – Vol. 20, Issue 5. – P. 326–331. doi: 10.1016/j.numecd.2009.04.002 

Соболева, Е. В. Гомоцистеинемия как мишень терапевтического воздействия у больных ишемической болезнью сердца. Эффекты симвастатина [Текст] / Е. В. Соболева // РМЖ. – 2007. – № 5. – С. 340.

Vladimirova-Kitova, L. G. Effect of Moderate and High-Dose Simvastatin on Asymmetric Dimethylarginine-Homocysteine Metabolic Pathways in Patients with Newly Detected Severe Hypercholesterolemia [Text] / L. G. Vladimirova-Kitova, T. I. Deneva, B. Marinov // Cardiovascular Therapeutics. – 2010. – Vol. 29, Issue 5. – P. 340–348. doi: 10.1111/j.1755-5922.2010.00149.x 

Jiang, S. Effect of Simvastatin on Plasma Homocysteine Levels and Its Modification by MTHFR C677T Polymorphism in Chinese Patients with Primary Hyperlipidemia [Text] / S. Jiang, Q. Chen, S. A. Venners, G. Zhong, Y.-H. Hsu, H. Xing et. al. // Cardiovascular Therapeutics. – 2013. – Vol. 31, Issue 4. – P. e27–e33. doi: 10.1111/1755-5922.12002 

Некрут, Д. О. Вплив гіпергомоцистеїнемії на формування неалкогольної жирової хвороби печінки у щурів [Текст] / Д. О. Некрут // Вісник морфології. – 2016. – Т. 22, № 1. – С. 40–45.

Wilinski, B. Carvedilol Induces Endogenous Hydrogen Sulfide Tissue Concentration Changes in Various Mouse Organs [Text] / B. Wilinski, J. Wilinski, E. Somogyi, J. Piotrowska, M. Goralska, B. Macura // Folia Biologica. – 2011. – Vol. 59, Issue 3. – P. 151–155. doi: 10.3409/fb59_3-4.151-155 

Пентюк, А. А. Определение фосфолипидов по образованию гидрофобного комплекса с феротиоцианатом аммония [Текст] / А. А. Пентюк, В. И. Гуцол, О. А. Яковлева // Лаб. дело. – 1987. – № 6. – С. 457–459.

Siddiqi, N. J. Investigation into the Distribution of Total, Free, Peptide-bound, Protein-bound, Soluble-and Insoluble-Collagen Hydroxyproline in Various Bovine Tissues [Text] / N. J. Siddiqi, A. S. Alhomida // BMB Reports. – 2003. – Vol. 36, Issue 2. – P. 154–158. doi: 10.5483/bmbrep.2003.36.2.154 

Martinez-Vega, R. Long-term omega-3 fatty acid supplementation prevents expression changes in cochlear homocysteine metabolism and ameliorates progressive hearing loss in C57BL/6J mice [Text] / R. Martinez-Vega, T. Partearroyo, N. Vallecillo, G. Varela-Moreiras, M. A. Pajares, I. Varela-Nieto // The Journal of Nutritional Biochemistry. – 2015. – Vol. 26, Issue 12. – P. 1424–1433. doi: 10.1016/j.jnutbio.2015.07.011 

Huang, T. Docosahexaenoic acid decreases plasma homocysteine via regulating enzyme activity and mRNA expression involved in methionine metabolism [Text] / T. Huang, M. L. Wahlqvist, D. Li // Nutrition. – 2010. – Vol. 26, Issue 1. – P. 112–119. doi: 10.1016/j.nut.2009.05.015 

Huang, T. Effect of n-3 polyunsaturated fatty acid on gene expression of the critical enzymes involved in homocysteine metabolism [Text] / T. Huang, M. L. Wahlqvist, D. Li // Nutrition Journal. – 2012. – Vol. 11, Issue 1. doi: 10.1186/1475-2891-11-6 

Mikael, L. G. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF- B/iNOS [Text] / L. G. Mikael, R. Rozen // Cardiovascular Research. – 2008. – Vol. 80, Issue 1. – P. 151–158. doi: 10.1093/cvr/cvn157 

Sekine, Y. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor [Text] / Y. Sekine, Y. Furuya, M. Nishii, H. Koike, H. Matsui, K. Suzuki // Biochemical and Biophysical Research Communications. – 2008. – Vol. Vol. 72, Issue 2. – P. 356–361. doi: 10.1016/j.bbrc.2008.05.043 

Shibata, T. Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells [Text] / T. Shibata, M. Tamura, N. Kabashima, R. Serino, M. Tokunaga, M. Matsumoto et. al. // Life Sciences. – 2009. – Vol. 84, Issue 21-22. – P. 725–731. doi: 10.1016/j.lfs.2009.02.022 

Forbes, K. Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation [Text] / K. Forbes, V. K. Shah, K. Siddals, J. M. Gibson, J. D. Aplin, M. Westwood // MHR: Basic science of reproductive medicine. – 2014. – Vol. 21, Issue 1. – P. 105–114. doi: 10.1093/molehr/gau093 

Jang, H. Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation [Text] / H. Jang, E. Hong, S. Park, H. Byun, D. Koh, M. Choi et. al. // Oncology Letters. – 2016. – Vol. 12, Issue 1. – P. 250–256. doi: 10.3892/ol.2016.4569 

Tran, L. V. Effect of omega-3 and omega-6 polyunsaturated fatty acid enriched diet on plasma IGF-1 and testosterone concentration, puberty and semen quality in male buffalo [Text] / L. V. Tran, B. A. Malla, A. N. Sharma, S. Kumar, N. Tyagi, A. K. Tyagi // Animal Reproduction Science. – 2016. – Vol. 173. – P. 63–72. doi: 10.1016/j.anireprosci.2016.08.012 

Gholamhosseini, S. ω-3 fatty acid differentially modulated serum levels of IGF1 and IGFBP3 in men with CVD: A randomized, double-blind placebo-controlled study [Text] / S. Gholamhosseini, E. Nematipour, A. Djazayery, M. H. Javanbakht, F. Koohdani, M. Zareei, M. Djalali // Nutrition. – 2015. – Vol. 31, Issue 3. – P. 480–484. doi: 10.1016/j.nut.2014.09.010 







Copyright (c) 2017 Natalia Zaichko, Dar`ia Nekrut

Creative Commons License
Ця робота ліцензована Creative Commons Attribution 4.0 International License.

ISSN 2519-4798 (Online), ISSN 2519-478X (Print)